In retinal vein occlusion platelet response to thrombin is increased

Thrombosis Research

Volumn 124, Issue 6, 2009, Pages

  Leoncini, Giuliana ^a   Signorello, Maria Grazia ^a   Segantin, Alessia ^a   Giacobbe, Enrica ^a   Armani, Ugo ^b   Piana, Antonietta ^b   Camicione, Paola ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Human platelets; Retinal vein occlusion; Thrombin

Indexed keywords

ARACHIDONIC ACID; CALCIUM ION; CYTOSOLIC PHOSPHOLIPASE A2; MITOGEN ACTIVATED PROTEIN KINASE P38; SUPEROXIDE; THROMBIN; THROMBOXANE B2; TYROSINE;

ADULT; AGED; ARTICLE; CALCIUM CELL LEVEL; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RETINA VEIN OCCLUSION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

AGED; ARACHIDONIC ACID; BLOOD PLATELETS; CASE-CONTROL STUDIES; CYTOSOL; FEMALE; HUMANS; MALE; MIDDLE AGED; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOLIPASES A2; RETINA; RETINAL VEIN OCCLUSION; RETINAL VESSELS; SUPEROXIDES; THROMBIN; THROMBOXANE B2; TREATMENT OUTCOME;

EID: 70449518270     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.07.010     Document Type: Article

References (36)

1. David R., Zangwill L., Badarna M., and Yassur Y. Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica 197 (1988) 69-74
2. Prisco D., and Marcucci R. Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb 32 (2002) 308-311
3. Marcucci R., Bertini L., Giusti B., Brunelli T., Fedi S., Cellai A.P., et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 86 (2001) 772-776
4. Arsène S., Delahousse B., Regina S., Le Lez M.L., Pisella P.J., and Gruel Y. Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age. Thromb Haemost 94 (2005) 101-106
5. D'Angelo A., Tavola A., Fermo I., Mazzola G., and Brancato R. Moderate hyperhomocysteinemia and central retinal vein occlusion. Thromb Haemost 87 (2002) 1078-1079
6. Gori A.M., Marcucci R., Fatini C., Gensini F., Sticchi E., Sodi A., et al. Impaired fibrinolysis in retinal vein occlusion: a role for genetic determinants of PAI-1 levels. Thromb Haemost 92 (2004) 54-60
7. Lippi G., and Guidi G. Lipoprotein(a): an emerging cardiovascular risk factor. Crit Rev Clin Lab Sci 40 (2003) 1-42
8. Lippi G., Franchini M., and Targher G. Platelets and lipoprotein(a) in retinal vein occlusion: mutual targets for aspirin therapy. Thromb Haemost 97 (2007) 1059-1060
9. Priluck I.A. Impending central retinal vein occlusion associated with increased platelet aggregability. Ann Ophthalmol 11 (1979) 79-84
10. Dodson P.M., Westwick J., Marks G., Kakkar V.V., and Galton D.J. beta-thromboglobulin and platelet factor 4 levels in retinal vein occlusion. Br J Ophthalmol 67 (1983) 143-146
11. Leoncini G., Bruzzese D., Signorello M.G., Armani U., Piana A., Ghiglione D., et al. Platelet activation by collagen is increased in retinal vein occlusion. Thromb Haemost 97 (2007) 218-227
12. Kramer R.M., and Sharp J.D. Structure, function and regulation of Ca2+-sensitive cytosolic phospholipase A2 (cPLA2). FEBS Lett 410 (1997) 49-53
13. Lin L.L., Lin A.Y., and Knopf J.L. Cytosolic phospholipase A2 is coupled to hormonally regulated release of arachidonic acid. Proc Natl Acad Sci U S A 89 (1992) 6147-6151
14. Kramer R.M., Roberts E.F., Strifler B.A., and Johnstone E.M. Thrombin induces activation of p38 MAP kinase in human platelets. J Biol Chem 270 (1995) 27395-27398
15. Kramer R.M., Roberts E.F., Um S.L., Börsch-Haubold A.G., Watson S.P., Fisher M.J., et al. p38 mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombin-stimulated platelets. Evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA2. J Biol Chem 271 (1996) 27723-27729
16. Saklatvala J., Rawlinson L., Waller R.J., Sarsfield S., Lee J.C., Morton L.F., et al. Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue. J Biol Chem 271 (1996) 6586-6589
17. Leoncini G., Bruzzese D., and Signorello M.G. Activation of p38 MAPKinase/cPLA2 pathway in homocysteine-treated platelets. J Thromb Haemost 20 (2006) 9-16
18. Hackeng C.M., Relou I.A., Pladet M.W., Gorter G., van Rijn H.J., and Akkerman J.W. Early platelet activation by low density lipoprotein via p38MAP kinase. Thromb Haemost 82 (1999) 1749-1756
19. Canobbio I., Reineri S., Sinigaglia F., Balduini C., and Torti M. A role for p38 MAP kinase in platelet activation by von Willebrand factor. Thromb Haemost 91 (2004) 102-110
20. Börsch-Haubold A.G., Bartoli F., Asselin J., Dudler T., Kramer R.M., Apitz-Castro R., et al. Identification of the phosphorylation sites of cytosolic phospholipase A2 in agonist-stimulated human platelets and HeLa cells. J Biol Chem 273 (1998) 4449-4458
21. Leoncini G., Maresca M., Buzzi E., Piana A., and Armani U. Platelets of patients affected with Essential Thrombocythemia are abnormal in plasma membrane and adenine nucleotide content. Eur J Haematol 44 (1990) 116-120
22. Born G.V.R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194 (1962) 927-929
23. Leoncini G., and Signorello M.G. N-Ethylmaleimide-stimulated arachidonic acid release in human platelets. Biochem Pharmacol 57 (1999) 785-791
24. Freedman J.E., and Keaney Jr. J.F. Nitric oxide and superoxide detection in human platelets. Methods Enzymol 301 (1999) 61-70
25. Coughlin S.R. Protease-activated receptors and platelet function. Thromb Haemost 82 (1999) 353-356
26. Kramer R.M., Roberts E.F., Hyslop P.A., Utterback B.G., Hui K.Y., and Jakubowski J.A. Differential activation of cytosolic phospholipase A2 (cPLA2) by thrombin and thrombin receptor agonist peptide in human platelets. Evidence for activation of cPLA2 independent of the mitogen-activated protein kinases ERK1/2. J Biol Chem 270 (1995) 14816-14823
27. Leslie C.C. Regulation of the specific release of arachidonic acid by cytosolic phospholipase A2. Prostaglandins Leukot Essent Fat Acids 70 (2004) 373-376
28. Krötz F., Sohn H.Y., and Pohl U. Reactive oxygen species: players in the platelet game. Arterioscler Thromb Vasc Biol 24 (2004) 1988-1996
29. Chlopicki S., Olszanecki R., Janiszewski M., Laurindo F.R., Panz T., and Miedzobrodzki J. Functional role of NADPH oxidase in activation of platelets. Antioxid Redox Signal 6 (2004) 691-698
30. Moro M.A., Darley-Usmar V.M., Goodwin D.A., Read N.G., Zamora-Pino R., Feelisch M., et al. Paradoxical fate and biological action of peroxynitrite on human platelets. Proc Natl Acad Sci U S A 91 (1994) 6702-6706
31. Green W.R., Chan C.C., Hutchins G.M., and Terry J.M. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc 79 (1981) 371-422
32. Beaumont P.E., and Kang H.K. Clinical characteristics of retinal venous occlusions occurring at different sites. Br J Ophthalmol 86 (2002) 572-580
33. Janssen M.C., den Heijer M., Cruysberg J.R., Wollersheim H., and Bredie S.J. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis?. Thromb Haemost 93 (2005) 1021-1026
34. Marcucci R., Giusti B., Betti I., Evangelisti L., Fedi S., Sodi A., et al. Genetic determinants of fasting and post-methionine hyperhomocysteinemia in patients with retinal vein occlusion. Thromb Res 110 (2003) 7-12
35. Piana A., Camicione P., Ghiglione D., Napoletano L., Sormani M.P., and Armani U. Thromboembolic risk factors in retinal vein occlusion: a comparison with other venous thrombosis. Haematologica 93 s3 (2008)
36. Faude F., Faude S., Siegemund A., and Wiedemann P. Factor VIII activity in patients with central retinal vein occlusion in comparison to patients with a history of pelvic and lower limb venous thrombosis and a healthy control group. Klin Monatsbl Augenheilkd 221 (2004) 862-866